Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16628128,flow-rate,"The mobile phase was acetonitrile-water (70:30) at a flow-rate of 1.0 mL/min, and the derivatives were eluted at 13.1 and 15.5 minutes for paroxetine and desipramine, respectively, and detected at 567 nm.","Determination of paroxetine in human plasma by high-performance liquid chromatography using 7,7,8,8-tetracyanoquinodimethane as the derivatization reagent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628128/),[ml] / [min],1.0,3755,DB01151,Desipramine
,16628128,detection limit,"Calibration curve was found linear over the range of 20-400 ng/mL, and the detection limit was 2 ng/mL at a signal-to-noise ratio of 3/1.","Determination of paroxetine in human plasma by high-performance liquid chromatography using 7,7,8,8-tetracyanoquinodimethane as the derivatization reagent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628128/),[ng] / [ml],2,3756,DB01151,Desipramine
,16628128,signal-to-noise ratio,"Calibration curve was found linear over the range of 20-400 ng/mL, and the detection limit was 2 ng/mL at a signal-to-noise ratio of 3/1.","Determination of paroxetine in human plasma by high-performance liquid chromatography using 7,7,8,8-tetracyanoquinodimethane as the derivatization reagent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628128/),,3/1,3757,DB01151,Desipramine
,16628128,Recoveries,Recoveries determined for 3 concentrations range between 81.3% and 88.1%.,"Determination of paroxetine in human plasma by high-performance liquid chromatography using 7,7,8,8-tetracyanoquinodimethane as the derivatization reagent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628128/),%,81.3,3758,DB01151,Desipramine
,16628128,Recoveries,Recoveries determined for 3 concentrations range between 81.3% and 88.1%.,"Determination of paroxetine in human plasma by high-performance liquid chromatography using 7,7,8,8-tetracyanoquinodimethane as the derivatization reagent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628128/),%,88.1,3759,DB01151,Desipramine
,7129805,elimination half-life,"Nomifensine serum levels were determined by a radioimmunoassay; peak levels occurred within the first 2 h, the elimination half-life was around 2 h, both results indicating fast absorption and elimination.",The pharmacokinetics of nomifensine. Comparison of pharmacokinetics and pharmacodynamics using computer pharmaco-EEG. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7129805/),h,2,4772,DB01151,Desipramine
,7320140,Detection limit,Detection limit was 3 ng.,Determination of 2-hydroxydesipramine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7320140/),ng,3,4914,DB01151,Desipramine
less,1815435,clearance,Two slow metabolizers were identified (clearance less than 0.10 L/kg/h).,Early individualization of tricyclic antidepressant dosing using a Bayesian pharmacokinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815435/),[l] / [h·kg],0.10,8081,DB01151,Desipramine
,2791284,minimum concentration,"This procedure for measuring desipramine and its 2-hydroxy metabolite in serum at a minimum concentration of 1 micrograms/L involves high-performance liquid chromatography (HPLC), with ultraviolet detection at 214 nm.",Determination of serum desipramine and 2-hydroxydesipramine for pharmacokinetic applications by HPLC with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791284/),[μg] / [l],1,9110,DB01151,Desipramine
,8059340,Peak heart binding,Peak heart binding of [11C]cocaine was high (0.038-0.055%/g) and clearance was rapid (t1/2 from peak: 2.5-9 min) for both tracer doses and a pharmacological dose.,PET studies of cocaine inhibition of myocardial norepinephrine uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059340/),[%] / [g],0.038-0.055,16336,DB01151,Desipramine
,8059340,t1/2 from peak,Peak heart binding of [11C]cocaine was high (0.038-0.055%/g) and clearance was rapid (t1/2 from peak: 2.5-9 min) for both tracer doses and a pharmacological dose.,PET studies of cocaine inhibition of myocardial norepinephrine uptake. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059340/),min,2.5-9,16337,DB01151,Desipramine
,3067542,clearance,Imipramine has a high clearance (0.8-1.5 l/min) and a corresponding high first pass elimination (30-70%).,Imipramine: a model substance in pharmacokinetic research. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067542/),[l] / [min],0.8-1.5,18111,DB01151,Desipramine
,3067542,Volume of distribution,Volume of distribution is high (650-1100 1) and half-lives accordingly of medium length (6-12 h).,Imipramine: a model substance in pharmacokinetic research. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067542/),1,650-1100,18112,DB01151,Desipramine
,3067542,half-lives,Volume of distribution is high (650-1100 1) and half-lives accordingly of medium length (6-12 h).,Imipramine: a model substance in pharmacokinetic research. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067542/),h,6-12,18113,DB01151,Desipramine
,6427820,t1/2,"The t1/2 of IMI and 2-hydroxyimipramine (2-OH-IMI) was 6-18 h, while that of DMI and 2- hydroxydesipramine (2-OH-DMI) was 12-36 h.",The analysis and disposition of imipramine and its active metabolites in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6427820/),h,6-18,20056,DB01151,Desipramine
,6427820,t1/2,"The t1/2 of IMI and 2-hydroxyimipramine (2-OH-IMI) was 6-18 h, while that of DMI and 2- hydroxydesipramine (2-OH-DMI) was 12-36 h.",The analysis and disposition of imipramine and its active metabolites in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6427820/),h,12-36,20057,DB01151,Desipramine
,12412819,C(max),"Terbinafine administration inhibited CYP2D6 metabolism, as indicated by the significant increase in desipramine C(max) (19 ng/ml vs. 36 ng/ml) and AUC0-infinity (482 ng.h/ml vs. 2383 ng.h/ml) and decrease in AUC0-24 and C(max) of the CYP2D6-mediated metabolite, 2-hydroxydesipramine.",Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412819/),[ng] / [ml],19,21697,DB01151,Desipramine
,12412819,C(max),"Terbinafine administration inhibited CYP2D6 metabolism, as indicated by the significant increase in desipramine C(max) (19 ng/ml vs. 36 ng/ml) and AUC0-infinity (482 ng.h/ml vs. 2383 ng.h/ml) and decrease in AUC0-24 and C(max) of the CYP2D6-mediated metabolite, 2-hydroxydesipramine.",Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412819/),[ng] / [ml],36,21698,DB01151,Desipramine
,12412819,AUC0-infinity,"Terbinafine administration inhibited CYP2D6 metabolism, as indicated by the significant increase in desipramine C(max) (19 ng/ml vs. 36 ng/ml) and AUC0-infinity (482 ng.h/ml vs. 2383 ng.h/ml) and decrease in AUC0-24 and C(max) of the CYP2D6-mediated metabolite, 2-hydroxydesipramine.",Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412819/),[h·ng] / [ml],482,21699,DB01151,Desipramine
,12412819,AUC0-infinity,"Terbinafine administration inhibited CYP2D6 metabolism, as indicated by the significant increase in desipramine C(max) (19 ng/ml vs. 36 ng/ml) and AUC0-infinity (482 ng.h/ml vs. 2383 ng.h/ml) and decrease in AUC0-24 and C(max) of the CYP2D6-mediated metabolite, 2-hydroxydesipramine.",Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412819/),[h·ng] / [ml],2383,21700,DB01151,Desipramine
,10391421,weight,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],47.26,22460,DB01151,Desipramine
,10391421,weight-,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],47.26,22461,DB01151,Desipramine
,10391421,dose-normalized serum concentrations,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],47.26,22462,DB01151,Desipramine
,10391421,dose-normalized serum concentrations,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],39.02,22463,DB01151,Desipramine
,10391421,clearance,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[l] / [kg],0.690,22464,DB01151,Desipramine
,10391421,clearance,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[l] / [kg],0.613,22465,DB01151,Desipramine
,15788540,kinact,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),1/[min],0.17,28928,DB01151,Desipramine
,15788540,unbound KI,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),μM,0.315,28929,DB01151,Desipramine
,15788540,degradation half-life,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),h,51,28930,DB01151,Desipramine
,15788540,degradation half-life,Simulation of the sensitivities of these predictions to model inputs suggests a 2-fold underprediction of interaction magnitude when a CYP2D6 degradation half-life of 14 h (reported for rat CYP3A) is used.,In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),h,14,28931,DB01151,Desipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,7.8,30263,DB01151,Desipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,11.6,30264,DB01151,Desipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,16,30265,DB01151,Desipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,17.8,30266,DB01151,Desipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,20.9,30267,DB01151,Desipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,31,30268,DB01151,Desipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,35,30269,DB01151,Desipramine
,16680561,"t (1/2,z)","The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).",Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680561/),hs,21.0,32558,DB01151,Desipramine
,16680561,"t (1/2,z)","The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).",Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680561/),hs,43.3,32559,DB01151,Desipramine
,2863107,mean residence time,The DMI concentration exceeded that of IMI in all tissues and DMI persisted in tissues longer: mean residence time for DMI in whole fetus was 21.2 hr compared to 3.5 hr for IMI.,Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863107/),h,21.2,35049,DB01151,Desipramine
,2863107,mean residence time,The DMI concentration exceeded that of IMI in all tissues and DMI persisted in tissues longer: mean residence time for DMI in whole fetus was 21.2 hr compared to 3.5 hr for IMI.,Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863107/),h,3.5,35050,DB01151,Desipramine
,20116349,total run time,The total run time was 3.5 min.,Simultaneous determination of citalopram and its metabolite in human plasma by LC-MS/MS applied to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20116349/),min,3.5,43264,DB01151,Desipramine
,20116349,runtime,"Compared to the best existing literatures for plasma samples, the same LOQ for CIT (0.5 ng/mL) and lower LOQ for DCIT (0.25 vs 5 ng/mL) were reached, and less sample preparation steps and runtime (3.5 vs 10 min) were taken for our method.",Simultaneous determination of citalopram and its metabolite in human plasma by LC-MS/MS applied to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20116349/),min,3.5,43265,DB01151,Desipramine
,20116349,runtime,"Compared to the best existing literatures for plasma samples, the same LOQ for CIT (0.5 ng/mL) and lower LOQ for DCIT (0.25 vs 5 ng/mL) were reached, and less sample preparation steps and runtime (3.5 vs 10 min) were taken for our method.",Simultaneous determination of citalopram and its metabolite in human plasma by LC-MS/MS applied to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20116349/),min,10,43266,DB01151,Desipramine
,2293407,Mean residence time,"Mean residence time for DMI was significantly longer than for IMI (47.1 +/- 21.2 vs. 13.4 +/- 4.8 h, p less than 0.001).",Model for the kinetics of imipramine and its metabolites in adolescents. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293407/),h,47.1,53167,DB01151,Desipramine
,2293407,Mean residence time,"Mean residence time for DMI was significantly longer than for IMI (47.1 +/- 21.2 vs. 13.4 +/- 4.8 h, p less than 0.001).",Model for the kinetics of imipramine and its metabolites in adolescents. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293407/),h,13.4,53168,DB01151,Desipramine
,2293407,Clearance,"Clearance of DMI was considerably slower than that of IMI (0.67 +/- 0.45 vs. 2.18 +/- 1.33 l(kg.h), p less than 0.001).",Model for the kinetics of imipramine and its metabolites in adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293407/),h)·l(kg,0.67,53169,DB01151,Desipramine
,2293407,Clearance,"Clearance of DMI was considerably slower than that of IMI (0.67 +/- 0.45 vs. 2.18 +/- 1.33 l(kg.h), p less than 0.001).",Model for the kinetics of imipramine and its metabolites in adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293407/),h)·l(kg,2.18,53170,DB01151,Desipramine
,3133701,dose-normalized steady-state concentration,"The mean (SEM) values of the dose-normalized steady-state concentration and the apparent clearance after oral administration of this drug were 25.8 (4.8) ng.ml-1/mg.kg-1 and 2.529 (0.342) 1.h-1.kg-1, respectively.",Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133701/),[ng] / [kg·mg·ml],25.8,53811,DB01151,Desipramine
,3133701,apparent clearance,"The mean (SEM) values of the dose-normalized steady-state concentration and the apparent clearance after oral administration of this drug were 25.8 (4.8) ng.ml-1/mg.kg-1 and 2.529 (0.342) 1.h-1.kg-1, respectively.",Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133701/),[1] / [h·kg],2.529,53812,DB01151,Desipramine
,3133701,dose-normalized steady-state concentration,"The mean dose-normalized steady-state concentration of IMI was 68.3 (19.7) ng.ml-1/mg.kg-1, and the mean apparent clearance after oral administration of IMI was 1.619 (0.353) 1.h-1. kg-1.",Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133701/),[ng] / [kg·mg·ml],68.3,53813,DB01151,Desipramine
,3133701,apparent clearance,"The mean dose-normalized steady-state concentration of IMI was 68.3 (19.7) ng.ml-1/mg.kg-1, and the mean apparent clearance after oral administration of IMI was 1.619 (0.353) 1.h-1. kg-1.",Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133701/),[1] / [h·kg],1.619,53814,DB01151,Desipramine
less,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,24,56611,DB01151,Desipramine
,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),d,2,56612,DB01151,Desipramine
,7834966,tmax,"All 3 of the structurally unique newer antidepressants [amfebutamone (bupropion), viloxazine venlafaxine] have relatively short tmax values (1 to 2 hours), which may relate to the early onset of adverse effects.",Pharmacokinetic optimisation of therapy with newer antidepressants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,1 to 2,56613,DB01151,Desipramine
,3350999,total active compounds,The average of total active compounds in smokers (239 ng/ml) was less (p less than 0.1) than in nonsmokers (524 ng/ml).,Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),[ng] / [ml],239,58686,DB01151,Desipramine
,3350999,total active compounds,The average of total active compounds in smokers (239 ng/ml) was less (p less than 0.1) than in nonsmokers (524 ng/ml).,Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),[ng] / [ml],524,58687,DB01151,Desipramine
,3350999,serum concentration ratios,"The mean serum concentration ratios were 0.24 for 2-OH-IMI/IMI and 0.50 for 2-OH-DMI/DMI ratios, whereas the DMI/IMI ratio was 1.88, indicating more extensive accumulation of DMI.",Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),,0.24,58688,DB01151,Desipramine
,3350999,serum concentration ratios,"The mean serum concentration ratios were 0.24 for 2-OH-IMI/IMI and 0.50 for 2-OH-DMI/DMI ratios, whereas the DMI/IMI ratio was 1.88, indicating more extensive accumulation of DMI.",Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),,0.50,58689,DB01151,Desipramine
,3350999,serum concentration ratios,Appreciable glucuronide conjugate accumulation occurred with average serum concentration ratios of 8.13 for GA-O-IMI/2-OH-IMI and 6.22 for GA-O-DMI/2-OH-DMI.,Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),,8.13,58690,DB01151,Desipramine
,3350999,serum concentration ratios,Appreciable glucuronide conjugate accumulation occurred with average serum concentration ratios of 8.13 for GA-O-IMI/2-OH-IMI and 6.22 for GA-O-DMI/2-OH-DMI.,Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),,6.22,58691,DB01151,Desipramine
,3350999,Renal clearances,"Renal clearances of 2-OH-DMI were 35 to 267 ml/min, whereas those of the conjugates were only 10 to 110 ml/min.",Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),[ml] / [min],35 to 267,58692,DB01151,Desipramine
,3350999,Renal clearances,"Renal clearances of 2-OH-DMI were 35 to 267 ml/min, whereas those of the conjugates were only 10 to 110 ml/min.",Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),[ml] / [min],10 to 110,58693,DB01151,Desipramine
less,6436888,total elution time,The total elution time was less than 15 min.,"Quantification of imipramine and its major metabolites in whole blood, brain, and other tissues of the rat by liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436888/),min,15,64324,DB01151,Desipramine
,7891324,molar Fab-to-DMI ratio,"Rats received 20 mg/kg DMI intravenously over 30 min followed in 10 min by DMI-specific ovine polyclonal Fab (DMI-Fab) or nonspecific human Fab (control-Fab) (1.1 g/kg; molar Fab-to-DMI ratio, 0.34) intravenously over 20 min.","Effects of specific antibody Fab fragments on desipramine pharmacokinetics in the rat in vivo and in the isolated, perfused liver. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891324/),,0.34,66026,DB01151,Desipramine
,7891324,molar ratio,"The percent of DMI bound in urine was markedly increased by DMI-Fab (87.1 vs. 19.1%), as was the molar ratio of DMI to DMI-Fab in urine (0.75 vs. 0.08).","Effects of specific antibody Fab fragments on desipramine pharmacokinetics in the rat in vivo and in the isolated, perfused liver. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891324/),,0.75,66027,DB01151,Desipramine
,7891324,molar ratio,"The percent of DMI bound in urine was markedly increased by DMI-Fab (87.1 vs. 19.1%), as was the molar ratio of DMI to DMI-Fab in urine (0.75 vs. 0.08).","Effects of specific antibody Fab fragments on desipramine pharmacokinetics in the rat in vivo and in the isolated, perfused liver. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891324/),,0.08,66028,DB01151,Desipramine
,7661425,time of maximal toxicity,"In the study of the interaction of TFab and NaHCO3, each rat received 30 mg/kg IP desipramine followed by TFab (molar TFab:desipramine ratio, .11), NaHCO3, TFab+NaHCO3, or NaCl at the time of maximal toxicity (15 minutes).",Reduction of desipramine cardiotoxicity and prolongation of survival in rats with the use of polyclonal drug-specific antibody Fab fragments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661425/),min,15,74305,DB01151,Desipramine
,8075879,intracerebral,3. The intracerebral half life (t1/2) of Imip was 2.4 +/- 0.3 h with Imip alone.,Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8075879/),h,2.4,75126,DB01151,Desipramine
,8075879,half life (t1/2),3. The intracerebral half life (t1/2) of Imip was 2.4 +/- 0.3 h with Imip alone.,Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8075879/),h,2.4,75127,DB01151,Desipramine
,3792426,t 1/2,Cimetidine preadministration statistically prolonged imipramine t 1/2 compared to ranitidine (22.7 vs. 13.0 h) or placebo (10.8 h).,The effect of ranitidine and cimetidine on imipramine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),h,22.7,82118,DB01151,Desipramine
,3792426,t 1/2,Cimetidine preadministration statistically prolonged imipramine t 1/2 compared to ranitidine (22.7 vs. 13.0 h) or placebo (10.8 h).,The effect of ranitidine and cimetidine on imipramine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),h,13.0,82119,DB01151,Desipramine
,3792426,t 1/2,Cimetidine preadministration statistically prolonged imipramine t 1/2 compared to ranitidine (22.7 vs. 13.0 h) or placebo (10.8 h).,The effect of ranitidine and cimetidine on imipramine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),h,10.8,82120,DB01151,Desipramine
,3792426,area under the curve (AUC),Mean imipramine area under the curve (AUC) following cimetidine pretreatment was more than double that following placebo (2.633 vs. 0.966 micrograms X h X ml-1) or ranitidine (1.14 micrograms X h X ml-1) pretreatment.,The effect of ranitidine and cimetidine on imipramine disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),[h·μg] / [ml],2.633,82121,DB01151,Desipramine
,3792426,area under the curve (AUC),Mean imipramine area under the curve (AUC) following cimetidine pretreatment was more than double that following placebo (2.633 vs. 0.966 micrograms X h X ml-1) or ranitidine (1.14 micrograms X h X ml-1) pretreatment.,The effect of ranitidine and cimetidine on imipramine disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),[h·μg] / [ml],0.966,82122,DB01151,Desipramine
,3792426,area under the curve (AUC),Mean imipramine area under the curve (AUC) following cimetidine pretreatment was more than double that following placebo (2.633 vs. 0.966 micrograms X h X ml-1) or ranitidine (1.14 micrograms X h X ml-1) pretreatment.,The effect of ranitidine and cimetidine on imipramine disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),[h·μg] / [ml],1.14,82123,DB01151,Desipramine
,1990238,molar ratio of,Animals were pretreated i.v. with 4.2 g/kg of a monoclonal antibody (anti-TCA) followed by DMI HCl 30 mg/kg i.p. (molar ratio of anti-TCA binding sites to DMI = 0.56).,Pretreatment with drug-specific antibody reduces desipramine cardiotoxicity in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1990238/),,0.56,85205,DB01151,Desipramine
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,4.4,93210,DB01151,Desipramine
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,7.5,93211,DB01151,Desipramine
,6636256,Absolute recoveries,Absolute recoveries were 87-97%.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),%,87-97,96511,DB01151,Desipramine
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],2,96512,DB01151,Desipramine
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],4,96513,DB01151,Desipramine
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],10,96514,DB01151,Desipramine
less,6636256,total assay time,The total assay time was less than 10 min for DESIP and 12 min for PRO.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),min,10,96515,DB01151,Desipramine
,6636256,total assay time,The total assay time was less than 10 min for DESIP and 12 min for PRO.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),min,12,96516,DB01151,Desipramine
,2792169,maximum concentrations,2-OH-Imipramine and 2-OH-desipramine were detected in plasma before (maximum concentrations 30-100 nmol.l-1) but not during quinidine.,Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792169/),[nM] / [l],30-100,97307,DB01151,Desipramine
,28398693,volume of distribution (Vss),"It shows a high volume of distribution (Vss) (10-50 L/kg) due to its high lipophilicity, unspecific phospholipid binding, and lysosomal trapping.",Development and Qualification of Physiologically Based Pharmacokinetic Models for Drugs With Atypical Distribution Behavior: A Desipramine Case Study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28398693/),[l] / [kg],10-50,97552,DB01151,Desipramine
,11430636,relative bioavailabilities,"The relative bioavailabilities of Tofranil 25 and Tofranil mite were 97% and 81%, respectively.",Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11430636/),%,97,111212,DB01151,Desipramine
,11430636,relative bioavailabilities,"The relative bioavailabilities of Tofranil 25 and Tofranil mite were 97% and 81%, respectively.",Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11430636/),%,81,111213,DB01151,Desipramine
,8333005,half-life,"Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001).",Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8333005/),h,22.8,113388,DB01151,Desipramine
,8333005,half-life,"Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001).",Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8333005/),h,40.5,113389,DB01151,Desipramine
,8333005,apparent oral clearance,"Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001).",Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8333005/),[l] / [h·kg],1.02,113390,DB01151,Desipramine
,8333005,apparent oral clearance,"Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001).",Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8333005/),[l] / [h·kg],0.28,113391,DB01151,Desipramine
,9549664,absolute bioavailability,The absolute bioavailability of venlafaxine was between 40% and 45% and was similar for both the CF and XR formulations.,Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549664/),%,40,113441,DB01151,Desipramine
,9549664,absolute bioavailability,The absolute bioavailability of venlafaxine was between 40% and 45% and was similar for both the CF and XR formulations.,Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549664/),%,45,113442,DB01151,Desipramine
,19015855,K(i),"In vitro studies with pooled human liver microsomes showed that temsirolimus and its principal metabolite, sirolimus, inhibit the CYP2D6 isozyme (K(i) = 1.5 and 5 microM, respectively), indicating potential for pharmacokinetic interaction with agents that are substrates of CYP2D6.","Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19015855/),μM,1.5,114042,DB01151,Desipramine
,19015855,K(i),"In vitro studies with pooled human liver microsomes showed that temsirolimus and its principal metabolite, sirolimus, inhibit the CYP2D6 isozyme (K(i) = 1.5 and 5 microM, respectively), indicating potential for pharmacokinetic interaction with agents that are substrates of CYP2D6.","Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19015855/),μM,5,114043,DB01151,Desipramine
,8513845,clearances,"During paroxetine, the median clearances were 22 l.h-1 and 18 l.h-1 in EMs and PMs respectively.",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],22,114647,DB01151,Desipramine
,8513845,clearances,"During paroxetine, the median clearances were 22 l.h-1 and 18 l.h-1 in EMs and PMs respectively.",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],18,114648,DB01151,Desipramine
,8513845,clearance via,"Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],56,114649,DB01151,Desipramine
,8513845,clearance via,"Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],1.4,114650,DB01151,Desipramine
,8513845,clearance via,"Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],6,114651,DB01151,Desipramine
,8513845,clearance via,"Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],2.9,114652,DB01151,Desipramine
,11417443,total oral clearance,"The median total oral clearance of desipramine was 372 l/h and 196 l/h [median difference 108 l/h (95.9% c.i., -304-598 l/h)] and the median partial clearance of desipramine by 2-hydroxylation was 155 l/h and 87 l/h [median difference 47 l/h (95.9% c.i., -124-141 l/h)] for the group with duplication and the group without duplication, respectively.",Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417443/),[l] / [h],372,114699,DB01151,Desipramine
,11417443,total oral clearance,"The median total oral clearance of desipramine was 372 l/h and 196 l/h [median difference 108 l/h (95.9% c.i., -304-598 l/h)] and the median partial clearance of desipramine by 2-hydroxylation was 155 l/h and 87 l/h [median difference 47 l/h (95.9% c.i., -124-141 l/h)] for the group with duplication and the group without duplication, respectively.",Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417443/),[l] / [h],196,114700,DB01151,Desipramine
,11417443,partial clearance,"The median total oral clearance of desipramine was 372 l/h and 196 l/h [median difference 108 l/h (95.9% c.i., -304-598 l/h)] and the median partial clearance of desipramine by 2-hydroxylation was 155 l/h and 87 l/h [median difference 47 l/h (95.9% c.i., -124-141 l/h)] for the group with duplication and the group without duplication, respectively.",Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417443/),[l] / [h],155,114701,DB01151,Desipramine
,11417443,partial clearance,"The median total oral clearance of desipramine was 372 l/h and 196 l/h [median difference 108 l/h (95.9% c.i., -304-598 l/h)] and the median partial clearance of desipramine by 2-hydroxylation was 155 l/h and 87 l/h [median difference 47 l/h (95.9% c.i., -124-141 l/h)] for the group with duplication and the group without duplication, respectively.",Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417443/),[l] / [h],87,114702,DB01151,Desipramine
,2255664,Run time,Run time was approximately 14 min.,An automated method for the determination of nortriptyline and its isomeric 10-hydroxylated metabolites in plasma by high pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255664/),min,14,117067,DB01151,Desipramine
,2255664,flow,"5 mu 250 x 4.6 mm column, a mobile phase consisting of aqueous ammonium: methanol: acetonitrile (0.8:6.2:93, v/v), and flow of 1.3 ml/min.",An automated method for the determination of nortriptyline and its isomeric 10-hydroxylated metabolites in plasma by high pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255664/),[ml] / [min],1.3,117068,DB01151,Desipramine
,1505617,elimination constant,"The mean value of the elimination constant of the drug and metabolite were 0.0425 h-1 and 0.0359, h-1 respectively.",Population pharmacokinetics of imipramine in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505617/),1/[h],0.0425,123947,DB01151,Desipramine
,1505617,elimination constant,"The mean value of the elimination constant of the drug and metabolite were 0.0425 h-1 and 0.0359, h-1 respectively.",Population pharmacokinetics of imipramine in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505617/),1/[h],0.0359,123948,DB01151,Desipramine
,9758674,Km,"Formation of OH-DMI from DMI was consistent with Michaelis-Menten kinetics, having a mean Km value of 11.7 microM (range: 9.9-15.3 microM).",Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758674/),μM,11.7,129119,DB01151,Desipramine
,9758674,inhibition constant,"Quinidine, a highly potent and relatively selective inhibitor of P450-2D6, strongly inhibited OH-DMI formation with an apparent competitive mechanism, having a mean inhibition constant of 0.16 microM (range: 0.13-0.18 microM).",Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758674/),μM,0.16,129120,DB01151,Desipramine
,9758674,inhibition constants,"Mean inhibition constants (small numbers indicating greater inhibiting potency) were as follows: ritonavir, 4.8 microM; indinavir, 15.6 microM; saquinavir, 24.0 microM; nelfinavir, 51.9 microM.",Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758674/),μM,4.8,129121,DB01151,Desipramine
,9758674,inhibition constants,"Mean inhibition constants (small numbers indicating greater inhibiting potency) were as follows: ritonavir, 4.8 microM; indinavir, 15.6 microM; saquinavir, 24.0 microM; nelfinavir, 51.9 microM.",Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758674/),μM,15.6,129122,DB01151,Desipramine
,9758674,inhibition constants,"Mean inhibition constants (small numbers indicating greater inhibiting potency) were as follows: ritonavir, 4.8 microM; indinavir, 15.6 microM; saquinavir, 24.0 microM; nelfinavir, 51.9 microM.",Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758674/),μM,24.0,129123,DB01151,Desipramine
,9758674,inhibition constants,"Mean inhibition constants (small numbers indicating greater inhibiting potency) were as follows: ritonavir, 4.8 microM; indinavir, 15.6 microM; saquinavir, 24.0 microM; nelfinavir, 51.9 microM.",Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758674/),μM,51.9,129124,DB01151,Desipramine
,1840130,retention times,"Under these conditions, the retention times of amlodipine and the internal standard desipramine were 10.6 and 12.9 min, respectively.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),min,10.6,130413,DB01151,Desipramine
,1840130,retention times,"Under these conditions, the retention times of amlodipine and the internal standard desipramine were 10.6 and 12.9 min, respectively.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),min,12.9,130414,DB01151,Desipramine
,1840130,sensitivity,"Using 1 ml of plasma, sensitivity of the assay was 2.5 ng ml-1 at which the RSD was 11%.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),[ng] / [ml],2.5,130415,DB01151,Desipramine
,1840130,half-life (t1/2),"The mean half-life (t1/2) of amlodipine was 6.5 h, the systemic clearance (CL) was 4.8 l h-1 kg-1 and the apparent volume of distribution at steady state (Vdss) was 30.2 l kg-1.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),h,6.5,130416,DB01151,Desipramine
,1840130,systemic clearance (CL),"The mean half-life (t1/2) of amlodipine was 6.5 h, the systemic clearance (CL) was 4.8 l h-1 kg-1 and the apparent volume of distribution at steady state (Vdss) was 30.2 l kg-1.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),[l] / [h·kg],4.8,130417,DB01151,Desipramine
,1840130,apparent volume of distribution at steady state (Vdss),"The mean half-life (t1/2) of amlodipine was 6.5 h, the systemic clearance (CL) was 4.8 l h-1 kg-1 and the apparent volume of distribution at steady state (Vdss) was 30.2 l kg-1.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),[l] / [kg],30.2,130418,DB01151,Desipramine
up to,19540084,Loading capacity,Loading capacity up to 25 microl of extract injected on column showed no peak distortion.,Comparison of fused-core and conventional particle size columns by LC-MS/MS and UV: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540084/),μl,25,145328,DB01151,Desipramine
,19540084,flow rate,The registered back-pressure from a flow rate of 1.0 ml/min did not exceed 3400 psi making it compatible with standard HPLC equipment (typically rated to 6000 psi).,Comparison of fused-core and conventional particle size columns by LC-MS/MS and UV: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540084/),[ml] / [min],1.0,145329,DB01151,Desipramine
not exceed,19540084,flow rate,The registered back-pressure from a flow rate of 1.0 ml/min did not exceed 3400 psi making it compatible with standard HPLC equipment (typically rated to 6000 psi).,Comparison of fused-core and conventional particle size columns by LC-MS/MS and UV: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540084/),psi,3400,145330,DB01151,Desipramine
,29038231,AUCR,"The AUCR static model estimations for clofazimine with the substrates midazolam, repaglinide, and desipramine were 5.59, 1.34, and 1.69, respectively.",Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29038231/),,5.59,150101,DB01151,Desipramine
,29038231,AUCR,"The AUCR static model estimations for clofazimine with the substrates midazolam, repaglinide, and desipramine were 5.59, 1.34, and 1.69, respectively.",Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29038231/),,1.34,150102,DB01151,Desipramine
,29038231,AUCR,"The AUCR static model estimations for clofazimine with the substrates midazolam, repaglinide, and desipramine were 5.59, 1.34, and 1.69, respectively.",Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29038231/),,1.69,150103,DB01151,Desipramine
,7604141,apparent oral clearance,"Compared with a control session, treatment with CBZ caused a marked increase in DMI apparent oral clearance (from 1.05 +/- 0.40 to 1.38 +/- 0.52 1 h per kg, means +/- SD, P < 0.01) and a significant shortening in DMI half-life (from 22.1 +/- 3.5 to 17.8 +/- 3.5 h, P < 0.01).",The effect of carbamazepine on the 2-hydroxylation of desipramine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7604141/),[1·h] / [kg],1.05,150283,DB01151,Desipramine
,7604141,apparent oral clearance,"Compared with a control session, treatment with CBZ caused a marked increase in DMI apparent oral clearance (from 1.05 +/- 0.40 to 1.38 +/- 0.52 1 h per kg, means +/- SD, P < 0.01) and a significant shortening in DMI half-life (from 22.1 +/- 3.5 to 17.8 +/- 3.5 h, P < 0.01).",The effect of carbamazepine on the 2-hydroxylation of desipramine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7604141/),[1·h] / [kg],1.38,150284,DB01151,Desipramine
,7604141,half-life,"Compared with a control session, treatment with CBZ caused a marked increase in DMI apparent oral clearance (from 1.05 +/- 0.40 to 1.38 +/- 0.52 1 h per kg, means +/- SD, P < 0.01) and a significant shortening in DMI half-life (from 22.1 +/- 3.5 to 17.8 +/- 3.5 h, P < 0.01).",The effect of carbamazepine on the 2-hydroxylation of desipramine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7604141/),h,22.1,150285,DB01151,Desipramine
,7604141,half-life,"Compared with a control session, treatment with CBZ caused a marked increase in DMI apparent oral clearance (from 1.05 +/- 0.40 to 1.38 +/- 0.52 1 h per kg, means +/- SD, P < 0.01) and a significant shortening in DMI half-life (from 22.1 +/- 3.5 to 17.8 +/- 3.5 h, P < 0.01).",The effect of carbamazepine on the 2-hydroxylation of desipramine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7604141/),h,17.8,150286,DB01151,Desipramine
,9004953,recovery,The recovery of diltiazem varied from 101.1% at 20 ng ml-1 to 93.7% at 400 ng ml-1.,High-performance liquid chromatographic assay for diltiazem in small-volume blood specimens and application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004953/),%,101.1,151294,DB01151,Desipramine
,9004953,recovery,The recovery of diltiazem varied from 101.1% at 20 ng ml-1 to 93.7% at 400 ng ml-1.,High-performance liquid chromatographic assay for diltiazem in small-volume blood specimens and application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004953/),%,93.7,151295,DB01151,Desipramine
,9004953,flow-rate through the system,The concentration of diltiazem in all test perfusion solutions was 1 mg ml-1 (2.4 mM) and the flow-rate through the system was 3.33.10(-3) ml s-1.,High-performance liquid chromatographic assay for diltiazem in small-volume blood specimens and application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004953/),[ml] / [s],3.33.10(-3),151296,DB01151,Desipramine
,9004953,AUC,"The pharmacokinetic data indicated that the AUC in the group which received the enhancer [18.12 +/- 5.43 ng ml-1 h-1 (+/- S.D.)] was higher than that in the control group (11.49 +/- 3.67 ng h-1 ml-1), t-test; p = 0.0483.",High-performance liquid chromatographic assay for diltiazem in small-volume blood specimens and application to pharmacokinetic studies in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004953/),[ng] / [h·ml],18.12,151297,DB01151,Desipramine
,9004953,AUC,"The pharmacokinetic data indicated that the AUC in the group which received the enhancer [18.12 +/- 5.43 ng ml-1 h-1 (+/- S.D.)] was higher than that in the control group (11.49 +/- 3.67 ng h-1 ml-1), t-test; p = 0.0483.",High-performance liquid chromatographic assay for diltiazem in small-volume blood specimens and application to pharmacokinetic studies in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004953/),[ng] / [h·ml],11.49,151298,DB01151,Desipramine
,1102994,bioavailability,The bioavailability of an orally administered dose of imipramine ranged between 29.5 and 54.7%.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),%,29.5 and 54.7,156590,DB01151,Desipramine
,1102994,half-lives,The half-lives of imipramine ranged from 4.0-17.6 hrs (M = 7.6 +/- 2.5) after single oral doses and between 9.2 and 20.2 hrs (M = 14.0 +/- 1.9) after multiple oral doses.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),h,4.0-17.6,156591,DB01151,Desipramine
,1102994,half-lives,The half-lives of imipramine ranged from 4.0-17.6 hrs (M = 7.6 +/- 2.5) after single oral doses and between 9.2 and 20.2 hrs (M = 14.0 +/- 1.9) after multiple oral doses.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),h,7.6,156592,DB01151,Desipramine
,1102994,half-lives,The half-lives of imipramine ranged from 4.0-17.6 hrs (M = 7.6 +/- 2.5) after single oral doses and between 9.2 and 20.2 hrs (M = 14.0 +/- 1.9) after multiple oral doses.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),h,9.2 and 20.2,156593,DB01151,Desipramine
,1102994,half-lives,The half-lives of imipramine ranged from 4.0-17.6 hrs (M = 7.6 +/- 2.5) after single oral doses and between 9.2 and 20.2 hrs (M = 14.0 +/- 1.9) after multiple oral doses.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),h,14.0,156594,DB01151,Desipramine
,1102994,half-lives,The half-lives of the formed desipramine ranged between 13.5 and 61.5 hrs (M = 29.9 +/- 8.7) after multiple oral doses of imipramine hydrochloride.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),h,13.5 and 61.5,156595,DB01151,Desipramine
,1102994,half-lives,The half-lives of the formed desipramine ranged between 13.5 and 61.5 hrs (M = 29.9 +/- 8.7) after multiple oral doses of imipramine hydrochloride.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),h,29.9,156596,DB01151,Desipramine
,1102994,steady-state plasma concentration,"The observed mean steady-state plasma concentration after multiple oral doses of imipramine hydrochloride, 50 mg t.i.d. varied from 21.4-69.0 mug/1 (M = 38.2 +/- 8.7) for imipramine and from 33.7-136.0 mug/1 (M 72.3 +/- 19.5) for desipramine.",Plasma levels of imipramine and desipramine in man after different routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),μg,21.4-69.0,156597,DB01151,Desipramine
,1102994,steady-state plasma concentration,"The observed mean steady-state plasma concentration after multiple oral doses of imipramine hydrochloride, 50 mg t.i.d. varied from 21.4-69.0 mug/1 (M = 38.2 +/- 8.7) for imipramine and from 33.7-136.0 mug/1 (M 72.3 +/- 19.5) for desipramine.",Plasma levels of imipramine and desipramine in man after different routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),μg,38.2,156598,DB01151,Desipramine
,1102994,steady-state plasma concentration,"The observed mean steady-state plasma concentration after multiple oral doses of imipramine hydrochloride, 50 mg t.i.d. varied from 21.4-69.0 mug/1 (M = 38.2 +/- 8.7) for imipramine and from 33.7-136.0 mug/1 (M 72.3 +/- 19.5) for desipramine.",Plasma levels of imipramine and desipramine in man after different routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),μg,33.7-136.0,156599,DB01151,Desipramine
,1102994,steady-state plasma concentration,"The observed mean steady-state plasma concentration after multiple oral doses of imipramine hydrochloride, 50 mg t.i.d. varied from 21.4-69.0 mug/1 (M = 38.2 +/- 8.7) for imipramine and from 33.7-136.0 mug/1 (M 72.3 +/- 19.5) for desipramine.",Plasma levels of imipramine and desipramine in man after different routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),,72.3,156600,DB01151,Desipramine
,2867146,Vdss,In the control rats the Vdss of imipramine was large at 19.9 litre kg-1.,Effect of phenobarbitone on the distribution and elimination of imipramine in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867146/),[l] / [kg],19.9,157550,DB01151,Desipramine
less,2867146,urinary excretion ratios,"The urinary excretion ratios of imipramine and desipramine, to the dose of imipramine over 8 h, were less than 1.5% in both groups.",Effect of phenobarbitone on the distribution and elimination of imipramine in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867146/),%,1.5,157551,DB01151,Desipramine
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,10,171113,DB01151,Desipramine
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,74,171114,DB01151,Desipramine
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,33,171115,DB01151,Desipramine
,14606931,bioavailabilities,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,26,171116,DB01151,Desipramine
,14606931,bioavailabilities,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,91,171117,DB01151,Desipramine
,14606931,Terminal disposition half-lives,"Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),h,2-3,171118,DB01151,Desipramine
,14606931,Terminal disposition half-lives,"Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),h,3-4,171119,DB01151,Desipramine
,6721989,total clearance of DMI ( CLDMI ),Mean total clearance of DMI ( CLDMI ) from plasma was significantly (P less than 0.05) higher in the Caucasians (123 +/- 57 l/h) than in the Chinese (73.5 +/- 38.8 l/h).,Desipramine pharmacokinetics in Chinese and Caucasian volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721989/),[l] / [h],123,171191,DB01151,Desipramine
,6721989,total clearance of DMI ( CLDMI ),Mean total clearance of DMI ( CLDMI ) from plasma was significantly (P less than 0.05) higher in the Caucasians (123 +/- 57 l/h) than in the Chinese (73.5 +/- 38.8 l/h).,Desipramine pharmacokinetics in Chinese and Caucasian volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721989/),[l] / [h],73.5,171192,DB01151,Desipramine
,9088587,apparent oral clearance,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[l] / [h·kg],1.16,180537,DB01151,Desipramine
,9088587,apparent oral clearance,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[l] / [h·kg],0.96,180538,DB01151,Desipramine
,9088587,half-life,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),h,16.7,180539,DB01151,Desipramine
,9088587,half-life,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),h,19.2,180540,DB01151,Desipramine
,9088587,area under the curve,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[h·nM] / [l],3507,180541,DB01151,Desipramine
,9088587,area under the curve,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[h·nM] / [l],3180,180542,DB01151,Desipramine
,6775331,apparent elimination half-life,"The apparent elimination half-life of imipramine was 20.8-34.9h (means 26.4h), its biovailability (F) was 40-64% (means 57%), and the apparent plasma clearance was from 0.27-0.57h/kg (mean 0.41h/kg).",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),h,20.8-34.9,182825,DB01151,Desipramine
,6775331,apparent elimination half-life,"The apparent elimination half-life of imipramine was 20.8-34.9h (means 26.4h), its biovailability (F) was 40-64% (means 57%), and the apparent plasma clearance was from 0.27-0.57h/kg (mean 0.41h/kg).",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),h,26.4,182826,DB01151,Desipramine
,6775331,biovailability (F),"The apparent elimination half-life of imipramine was 20.8-34.9h (means 26.4h), its biovailability (F) was 40-64% (means 57%), and the apparent plasma clearance was from 0.27-0.57h/kg (mean 0.41h/kg).",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),%,40-64,182827,DB01151,Desipramine
,6775331,biovailability (F),"The apparent elimination half-life of imipramine was 20.8-34.9h (means 26.4h), its biovailability (F) was 40-64% (means 57%), and the apparent plasma clearance was from 0.27-0.57h/kg (mean 0.41h/kg).",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),%,57,182828,DB01151,Desipramine
,6775331,apparent plasma clearance,"The apparent elimination half-life of imipramine was 20.8-34.9h (means 26.4h), its biovailability (F) was 40-64% (means 57%), and the apparent plasma clearance was from 0.27-0.57h/kg (mean 0.41h/kg).",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),[h] / [kg],0.41,182829,DB01151,Desipramine
,6775331,half-life,"Maprotiline had a longer half-life (mean 31.5h range 20.6-51.8h, but its bioavailability (mean 50%) and plasma clearance (mean 0.49h/kg) values were in the range similar to those seen after imipramine.",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),h,31.5,182830,DB01151,Desipramine
,6775331,bioavailability,"Maprotiline had a longer half-life (mean 31.5h range 20.6-51.8h, but its bioavailability (mean 50%) and plasma clearance (mean 0.49h/kg) values were in the range similar to those seen after imipramine.",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),%,50,182831,DB01151,Desipramine
,6775331,plasma clearance,"Maprotiline had a longer half-life (mean 31.5h range 20.6-51.8h, but its bioavailability (mean 50%) and plasma clearance (mean 0.49h/kg) values were in the range similar to those seen after imipramine.",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),[h] / [kg],0.49,182832,DB01151,Desipramine
above,2185906,steady-state plasma concentrations,"In at least a third of the population, nonlinear pharmacokinetics of desipramine may be observed at steady-state plasma concentrations above 150 micrograms/L.",Clinical pharmacokinetics of imipramine and desipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185906/),[μg] / [l],150,190551,DB01151,Desipramine
,3365915,total body clearance,Alcoholics had significantly greater total body clearance of imipramine (0.93 vs. 0.48 L/hr/kg; P less than 0.05) and desipramine (1.00 vs. 0.62 L/hr/kg; P less than 0.05) than did control subjects.,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [h·kg],0.93,191305,DB01151,Desipramine
,3365915,total body clearance,Alcoholics had significantly greater total body clearance of imipramine (0.93 vs. 0.48 L/hr/kg; P less than 0.05) and desipramine (1.00 vs. 0.62 L/hr/kg; P less than 0.05) than did control subjects.,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [h·kg],0.48,191306,DB01151,Desipramine
,3365915,total body clearance,Alcoholics had significantly greater total body clearance of imipramine (0.93 vs. 0.48 L/hr/kg; P less than 0.05) and desipramine (1.00 vs. 0.62 L/hr/kg; P less than 0.05) than did control subjects.,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [h·kg],1.00,191307,DB01151,Desipramine
,3365915,total body clearance,Alcoholics had significantly greater total body clearance of imipramine (0.93 vs. 0.48 L/hr/kg; P less than 0.05) and desipramine (1.00 vs. 0.62 L/hr/kg; P less than 0.05) than did control subjects.,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [h·kg],0.62,191308,DB01151,Desipramine
,3365915,Intrinsic clearance,"Intrinsic clearance of unbound imipramine was greater in the alcoholic group (19.80 vs. 6.56 L/hr/kg; P less than 0.05), as was the intrinsic clearance of unbound desipramine (14.52 vs. 9.05 L/hr/kg; P less than 0.05).",Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [h·kg],19.80,191309,DB01151,Desipramine
,3365915,Intrinsic clearance,"Intrinsic clearance of unbound imipramine was greater in the alcoholic group (19.80 vs. 6.56 L/hr/kg; P less than 0.05), as was the intrinsic clearance of unbound desipramine (14.52 vs. 9.05 L/hr/kg; P less than 0.05).",Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [h·kg],6.56,191310,DB01151,Desipramine
,3365915,intrinsic clearance of unbound desipramine,"Intrinsic clearance of unbound imipramine was greater in the alcoholic group (19.80 vs. 6.56 L/hr/kg; P less than 0.05), as was the intrinsic clearance of unbound desipramine (14.52 vs. 9.05 L/hr/kg; P less than 0.05).",Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [h·kg],14.52,191311,DB01151,Desipramine
,3365915,intrinsic clearance of unbound desipramine,"Intrinsic clearance of unbound imipramine was greater in the alcoholic group (19.80 vs. 6.56 L/hr/kg; P less than 0.05), as was the intrinsic clearance of unbound desipramine (14.52 vs. 9.05 L/hr/kg; P less than 0.05).",Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [h·kg],9.05,191312,DB01151,Desipramine
,3365915,elimination half-life,The mean elimination half-life for imipramine was significantly decreased in alcoholics (8.7 vs.,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),,8.7,191313,DB01151,Desipramine
,3365915,elimination half-life,The mean elimination half-life for desipramine was decreased in alcoholics after intravenous infusion (16.5 vs. 22.4 hours; P less than 0.05).,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),h,16.5,191314,DB01151,Desipramine
,3365915,elimination half-life,The mean elimination half-life for desipramine was decreased in alcoholics after intravenous infusion (16.5 vs. 22.4 hours; P less than 0.05).,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),h,22.4,191315,DB01151,Desipramine
,9241008,maximum concentration in plasma (Cmax),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],37.8 to 173,192832,DB01151,Desipramine
,9241008,maximum concentration in plasma (Cmax),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],36.1 to 51.9,192833,DB01151,Desipramine
,9241008,area under the concentration-time curve (AUC[24]),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[h·ng] / [ml],"634 to 3,305",192834,DB01151,Desipramine
,9241008,area under the concentration-time curve (AUC[24]),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[h·ng] / [ml],611 to 838,192835,DB01151,Desipramine
,9241008,trough value (C0),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],18.5 to 113,192836,DB01151,Desipramine
,9241008,trough value (C0),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],18.3 to 21.8,192837,DB01151,Desipramine
,32879225,activation energy (Ea),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[kj] / [mol],88.70,195214,DB01151,Desipramine
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],-,195215,DB01151,Desipramine
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],80.73,195216,DB01151,Desipramine
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,3,195217,DB01151,Desipramine
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,30,195218,DB01151,Desipramine
,1126113,systemic availability,The systemic availability of orally administered imipramine (IP) varied from 29 to 77% in 4 subjects.,First-pass metabolism of imipramine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1126113/),%,29 to 77,195752,DB01151,Desipramine
,18094213,prostate-to-seminal vesicles concentration ratio,The prostate-to-seminal vesicles concentration ratio was 0.20 (0.0087-0.75) for salicylate and 3.6 (0.91-9.9) for desipramine.,Noninvasive quantitation of drug concentration in prostate and seminal vesicles: improvement and validation with desipramine and aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094213/),,0.20,202208,DB01151,Desipramine
,18094213,prostate-to-seminal vesicles concentration ratio,The prostate-to-seminal vesicles concentration ratio was 0.20 (0.0087-0.75) for salicylate and 3.6 (0.91-9.9) for desipramine.,Noninvasive quantitation of drug concentration in prostate and seminal vesicles: improvement and validation with desipramine and aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094213/),,3.6,202209,DB01151,Desipramine
less,3988975,"""metabolic ratio""","The ""metabolic ratio"" of urinary debrisoquine to 4-OHD was less than 3 in all 20 subjects, indicating extensive debrisoquine hydroxylation in every volunteer, including two Chinese individuals known to display slow clearance of desipramine.",Interethnic dissociation between debrisoquine and desipramine hydroxylation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988975/),,3,205156,DB01151,Desipramine
,6726654,elimination half-life,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),h,22.1,206980,DB01151,Desipramine
,6726654,elimination half-life,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),h,15.5,206981,DB01151,Desipramine
,6726654,total metabolic clearance,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ml] / [min],623,206982,DB01151,Desipramine
,6726654,total metabolic clearance,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ml] / [min],1048,206983,DB01151,Desipramine
,6726654,volume of distribution,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[l] / [kg],17.2,206984,DB01151,Desipramine
,6726654,volume of distribution,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[l] / [kg],19.8,206985,DB01151,Desipramine
,6726654,unbound percent,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),%,17.7,206986,DB01151,Desipramine
,6726654,unbound percent,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),%,16.5,206987,DB01151,Desipramine
,6726654,peak imipramine blood levels,"After single p.o. imipramine doses, peak imipramine blood levels achieved were greater during cimetidine therapy (34.4 vs. 19.3 ng/ml, P less than .05) and area under the time/concentration curve was greatly increased (569 vs. 306 ng/ml X hr, P less than .05).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [ml],34.4,206988,DB01151,Desipramine
,6726654,peak imipramine blood levels,"After single p.o. imipramine doses, peak imipramine blood levels achieved were greater during cimetidine therapy (34.4 vs. 19.3 ng/ml, P less than .05) and area under the time/concentration curve was greatly increased (569 vs. 306 ng/ml X hr, P less than .05).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [ml],19.3,206989,DB01151,Desipramine
,6726654,area under the time/concentration curve,"After single p.o. imipramine doses, peak imipramine blood levels achieved were greater during cimetidine therapy (34.4 vs. 19.3 ng/ml, P less than .05) and area under the time/concentration curve was greatly increased (569 vs. 306 ng/ml X hr, P less than .05).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [h·ml],569,206990,DB01151,Desipramine
,6726654,area under the time/concentration curve,"After single p.o. imipramine doses, peak imipramine blood levels achieved were greater during cimetidine therapy (34.4 vs. 19.3 ng/ml, P less than .05) and area under the time/concentration curve was greatly increased (569 vs. 306 ng/ml X hr, P less than .05).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [h·ml],306,206991,DB01151,Desipramine
,6726654,area under the time/concentration curve,"Desipramine area under the time/concentration curve was increased during cimetidine therapy after p.o. imipramine doses (274 vs. 152 ng/ml X hr, P less than .05), suggesting that desipramine clearance was inhibited as well.",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [h·ml],274,206992,DB01151,Desipramine
,6726654,area under the time/concentration curve,"Desipramine area under the time/concentration curve was increased during cimetidine therapy after p.o. imipramine doses (274 vs. 152 ng/ml X hr, P less than .05), suggesting that desipramine clearance was inhibited as well.",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [h·ml],152,206993,DB01151,Desipramine
,6726654,absolute bioavailability,Comparison of i.v. and p.o. imipramine doses indicated absolute bioavailability was 40.2% in the control state and increased to 75.3% (P less than .05) during cimetidine treatment.,Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),%,40.2,206994,DB01151,Desipramine
,6726654,absolute bioavailability,Comparison of i.v. and p.o. imipramine doses indicated absolute bioavailability was 40.2% in the control state and increased to 75.3% (P less than .05) during cimetidine treatment.,Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),%,75.3,206995,DB01151,Desipramine
,20840444,first order absorption rate constant (k(a) ),"The mean population estimates of the first order absorption rate constant (k(a) ), apparent clearance (CL/F) and apparent volume of distribution at steady state (V(ss) /F) were 0.15h(-1) , 111 lh(-1) and 2950 l, respectively.","Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840444/),1/[h],0.15,207792,DB01151,Desipramine
,20840444,apparent clearance (CL/F),"The mean population estimates of the first order absorption rate constant (k(a) ), apparent clearance (CL/F) and apparent volume of distribution at steady state (V(ss) /F) were 0.15h(-1) , 111 lh(-1) and 2950 l, respectively.","Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840444/),1/[lh],111,207793,DB01151,Desipramine
,20840444,apparent volume of distribution at steady state (V(ss) /F),"The mean population estimates of the first order absorption rate constant (k(a) ), apparent clearance (CL/F) and apparent volume of distribution at steady state (V(ss) /F) were 0.15h(-1) , 111 lh(-1) and 2950 l, respectively.","Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840444/),l,2950,207794,DB01151,Desipramine
,20840444,hepatic intrinsic clearance,"Further, using the proposed semi-mechanistic hepatic intrinsic clearance model with Bayesian inference, mean population desipramine hepatic intrinsic clearance was estimated to be 262 lh(-1) with between-subject variability of 84%.","Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840444/),1/[lh],262,207795,DB01151,Desipramine
,1544284,oral clearance,"Desipramine oral clearance values were 289, 112, and 27 L/hr alone, after a single fluoxetine dose, and after multiple fluoxetine doses, respectively.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],289,219612,DB01151,Desipramine
,1544284,oral clearance,"Desipramine oral clearance values were 289, 112, and 27 L/hr alone, after a single fluoxetine dose, and after multiple fluoxetine doses, respectively.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],112,219613,DB01151,Desipramine
,1544284,oral clearance,"Desipramine oral clearance values were 289, 112, and 27 L/hr alone, after a single fluoxetine dose, and after multiple fluoxetine doses, respectively.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],27,219614,DB01151,Desipramine
,1544284,oral clearance,"Correspondingly, imipramine oral clearance values were 181, 87, and 51 L/hr.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],181,219615,DB01151,Desipramine
,1544284,oral clearance,"Correspondingly, imipramine oral clearance values were 181, 87, and 51 L/hr.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],87,219616,DB01151,Desipramine
,1544284,oral clearance,"Correspondingly, imipramine oral clearance values were 181, 87, and 51 L/hr.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],51,219617,DB01151,Desipramine
,4020379,elimination half-life,"Her elimination half-life for desipramine was found to be greatly prolonged, at approximately 150 hours.",Idiosyncratic pharmacokinetics complicating treatment of major depression in an elderly woman. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020379/),h,150,220633,DB01151,Desipramine
,9172016,Fab',"The affinity of G5-sFv for desipramine was similar to that of the corresponding monoclonal Fab' as measured by surface plasmon resonance (Fab' 5.5 +/- 0.5 x 10(8) M-1, sFv 2.3 +/- 0.5 x 10(8) M-1).",Bacterial expression and characterization of an anti-desipramine single-chain antibody fragment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9172016/),1/[M],5.5,222074,DB01151,Desipramine
,9172016,sFv,"The affinity of G5-sFv for desipramine was similar to that of the corresponding monoclonal Fab' as measured by surface plasmon resonance (Fab' 5.5 +/- 0.5 x 10(8) M-1, sFv 2.3 +/- 0.5 x 10(8) M-1).",Bacterial expression and characterization of an anti-desipramine single-chain antibody fragment. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9172016/),1/[M],2.3,222075,DB01151,Desipramine
,1794155,maximal brain concentrations (Cmax),"After single i.p. application of IMI, maximal brain concentrations (Cmax) of IMI and DMI were nearly twofold higher in darkness (IMI, 4.8 micrograms/g; DMI, 1.8 micrograms/g) than in light (IMI, 2.85 micrograms/g; DMI, 0.85 microgram/g).",Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1794155/),[μg] / [g],4.8,222764,DB01151,Desipramine
,1794155,maximal brain concentrations (Cmax),"After single i.p. application of IMI, maximal brain concentrations (Cmax) of IMI and DMI were nearly twofold higher in darkness (IMI, 4.8 micrograms/g; DMI, 1.8 micrograms/g) than in light (IMI, 2.85 micrograms/g; DMI, 0.85 microgram/g).",Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1794155/),μ,1.8,222765,DB01151,Desipramine
,1794155,maximal brain concentrations (Cmax),"After single i.p. application of IMI, maximal brain concentrations (Cmax) of IMI and DMI were nearly twofold higher in darkness (IMI, 4.8 micrograms/g; DMI, 1.8 micrograms/g) than in light (IMI, 2.85 micrograms/g; DMI, 0.85 microgram/g).",Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1794155/),[μg] / [g],2.85,222766,DB01151,Desipramine
,1794155,maximal brain concentrations (Cmax),"After single i.p. application of IMI, maximal brain concentrations (Cmax) of IMI and DMI were nearly twofold higher in darkness (IMI, 4.8 micrograms/g; DMI, 1.8 micrograms/g) than in light (IMI, 2.85 micrograms/g; DMI, 0.85 microgram/g).",Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1794155/),[μg] / [g],0.85,222767,DB01151,Desipramine
,7460470,plasma,"Desipramine reduced the plasma norepinephrine clearance by approximately 20%, from 1.33 +/- 0.22 to 1.08 +/- 0.19 l/m2/min (p less than 0.01).",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),[l] / [m2·min],1.33,223174,DB01151,Desipramine
,7460470,plasma,"Desipramine reduced the plasma norepinephrine clearance by approximately 20%, from 1.33 +/- 0.22 to 1.08 +/- 0.19 l/m2/min (p less than 0.01).",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),[l] / [m2·min],1.08,223175,DB01151,Desipramine
,7460470,clearance,"Desipramine reduced the plasma norepinephrine clearance by approximately 20%, from 1.33 +/- 0.22 to 1.08 +/- 0.19 l/m2/min (p less than 0.01).",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),[l] / [m2·min],1.33,223176,DB01151,Desipramine
,7460470,clearance,"Desipramine reduced the plasma norepinephrine clearance by approximately 20%, from 1.33 +/- 0.22 to 1.08 +/- 0.19 l/m2/min (p less than 0.01).",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),[l] / [m2·min],1.08,223177,DB01151,Desipramine
,7460470,rate of spillover,"Desipramine also reduced the rate of spillover of norepinephrine to plasma, 0.27 +/- 0.07 to 0.15 +/- 0.04 micrograms/m2/min, leaving the plasma norepinephrine concentration unchanged.",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),[μg] / [m2·min],0.27,223178,DB01151,Desipramine
,7460470,rate of spillover,"Desipramine also reduced the rate of spillover of norepinephrine to plasma, 0.27 +/- 0.07 to 0.15 +/- 0.04 micrograms/m2/min, leaving the plasma norepinephrine concentration unchanged.",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),[μg] / [m2·min],0.15,223179,DB01151,Desipramine
,7460470,half-time of the rapid-removal phase (t1 1/2),"Disappearance of tritiated norepinephrine from plasma, after infusion to steady state, was biexponential, with half-time of the rapid-removal phase (t1 1/2) = 2.0 +/- 0.4 min and half-time of the second exponential (t2 1/2) = 34 +/- 10 min.",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),min,2.0,223180,DB01151,Desipramine
,7460470,half-time of the second exponential (t2 1/2),"Disappearance of tritiated norepinephrine from plasma, after infusion to steady state, was biexponential, with half-time of the rapid-removal phase (t1 1/2) = 2.0 +/- 0.4 min and half-time of the second exponential (t2 1/2) = 34 +/- 10 min.",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),min,34,223181,DB01151,Desipramine
,30564074,extraction recoveries,"Under the optimum experimental conditions, extraction recoveries and enrichment factors of the selected drugs ranged from 69-84 % and 345-420, respectively.",Determination of tricyclic antidepressants in human urine samples by the three-step sample pretreatment followed by HPLC-UV analysis: an efficient analytical method for further pharmacokinetic and forensic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564074/),%,69-84,227547,DB01151,Desipramine
,30564074,enrichment factors,"Under the optimum experimental conditions, extraction recoveries and enrichment factors of the selected drugs ranged from 69-84 % and 345-420, respectively.",Determination of tricyclic antidepressants in human urine samples by the three-step sample pretreatment followed by HPLC-UV analysis: an efficient analytical method for further pharmacokinetic and forensic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564074/),,345-420,227548,DB01151,Desipramine
,4010387,t1/2 TERM,Pharmacokinetic analyses by HPLC method with fluorescence detection demonstrated a dose-dependent rapid rise in plasma concentrations peaking in the 1st hr and declining rapidly thereafter (t1/2 TERM = 3 hrs).,"On acute and chronic CNS effects of antidepressants in normals: neurophysiological, behavioral and pharmacokinetic studies with pirlindol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010387/),h,3,229038,DB01151,Desipramine
,9839087,distribution volume,"At steady-state, acamprosate has a moderate distribution volume of about 20L.",Clinical pharmacokinetics of acamprosate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),l,20,229746,DB01151,Desipramine
,9839087,terminal,The administration of the enteric-coated tablets showed a flip-flop mechanism with a terminal elimination half-life 10-fold higher than the 3-hour half-life reported after intravenous infusion.,Clinical pharmacokinetics of acamprosate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),h,3,229747,DB01151,Desipramine
,9839087,accumulation ratio,"The pharmacokinetics of acamprosate administered as an enteric-coated tablets are time- and dose-independent, and its accumulation ratio is about 2.4 at steady-state.",Clinical pharmacokinetics of acamprosate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),,2.4,229748,DB01151,Desipramine
,11292004,steady-state total serum concentrations,After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed.,Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11292004/),[ng] / [ml],168.84,232536,DB01151,Desipramine
,11292004,steady-state total serum concentrations,After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed.,Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11292004/),[ng] / [ml],98.12,232537,DB01151,Desipramine
,11292004,steady-state total serum concentrations,After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed.,Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11292004/),[ng] / [ml],293.89,232538,DB01151,Desipramine
,11292004,steady-state total serum concentrations,After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed.,Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11292004/),[ng] / [ml],221.85,232539,DB01151,Desipramine
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,10.1,237702,DB01151,Desipramine
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,10.5,237703,DB01151,Desipramine
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,7.5,237704,DB01151,Desipramine
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,7.0,237705,DB01151,Desipramine
,412206,half-lives,The half-lives of clomipramine after oral administration ranged from 11.6-35.8 h (M = 20.8 +/- 4.0) and after intramuscular administration from 20.1--39.6 h (M = 24.7 +/- 3.7).,The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412206/),h,11.6-35.8,239135,DB01151,Desipramine
,412206,half-lives,The half-lives of clomipramine after oral administration ranged from 11.6-35.8 h (M = 20.8 +/- 4.0) and after intramuscular administration from 20.1--39.6 h (M = 24.7 +/- 3.7).,The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412206/),h,20.8,239136,DB01151,Desipramine
,412206,half-lives,The half-lives of clomipramine after oral administration ranged from 11.6-35.8 h (M = 20.8 +/- 4.0) and after intramuscular administration from 20.1--39.6 h (M = 24.7 +/- 3.7).,The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412206/),h,20.1--39.6,239137,DB01151,Desipramine
,412206,half-lives,The half-lives of clomipramine after oral administration ranged from 11.6-35.8 h (M = 20.8 +/- 4.0) and after intramuscular administration from 20.1--39.6 h (M = 24.7 +/- 3.7).,The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412206/),,24.7,239138,DB01151,Desipramine
,9812178,t1/2 beta,The clinically relevant t1/2 beta is about 3 to 5 hours.,Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812178/),h,3 to 5,239662,DB01151,Desipramine
,9812178,apparent oral clearance,"The pharmacokinetics of ritonavir are relatively linear after multiple doses, with apparent oral clearance averaging 7 to 9 L/h.",Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812178/),[l] / [h],7 to 9,239663,DB01151,Desipramine
,23728524,half-life,Mean metoprolol half-life increased from 2.96 to 4.11 h.,"The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23728524/),h,2.96,240571,DB01151,Desipramine
,23728524,half-life,Mean metoprolol half-life increased from 2.96 to 4.11 h.,"The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23728524/),h,4,240572,DB01151,Desipramine
,23728524,half-life,Mean desipramine half-life increased from 19.5 to 35.8 h.,"The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23728524/),h,19.5,240573,DB01151,Desipramine
,23728524,half-life,Mean desipramine half-life increased from 19.5 to 35.8 h.,"The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23728524/),h,35,240574,DB01151,Desipramine
,3965690,half-life,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,28.6,243635,DB01151,Desipramine
,3965690,half-life,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,16.5,243636,DB01151,Desipramine
,3965690,half-life,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,30.2,243637,DB01151,Desipramine
,3965690,half-life,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,17.8,243638,DB01151,Desipramine
,3965690,clearance,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ml] / [min],567,243639,DB01151,Desipramine
,3965690,clearance,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ml] / [min],945,243640,DB01151,Desipramine
,3965690,clearance,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ml] / [min],599,243641,DB01151,Desipramine
,3965690,clearance,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ml] / [min],975,243642,DB01151,Desipramine
,3965690,time to peak imipramine concentration,After p.o. imipramine doses time to peak imipramine concentration was shorter in elderly females (2.1 vs. 4.8 hr; P less than .005) but no different in males.,Imipramine and desipramine disposition in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,2.1,243643,DB01151,Desipramine
,3965690,time to peak imipramine concentration,After p.o. imipramine doses time to peak imipramine concentration was shorter in elderly females (2.1 vs. 4.8 hr; P less than .005) but no different in males.,Imipramine and desipramine disposition in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,4.8,243644,DB01151,Desipramine
,3965690,Peak concentration achieved,"Peak concentration achieved was greater in the elderly of both sexes (males: 40.2 vs. 19.5 ng/ml, P less than .005; females: 44.7 vs. 10.4 ng/ml, P less than .01).",Imipramine and desipramine disposition in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ng] / [ml],40.2,243645,DB01151,Desipramine
,3965690,Peak concentration achieved,"Peak concentration achieved was greater in the elderly of both sexes (males: 40.2 vs. 19.5 ng/ml, P less than .005; females: 44.7 vs. 10.4 ng/ml, P less than .01).",Imipramine and desipramine disposition in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ng] / [ml],19.5,243646,DB01151,Desipramine
,3965690,Peak concentration achieved,"Peak concentration achieved was greater in the elderly of both sexes (males: 40.2 vs. 19.5 ng/ml, P less than .005; females: 44.7 vs. 10.4 ng/ml, P less than .01).",Imipramine and desipramine disposition in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ng] / [ml],44.7,243647,DB01151,Desipramine
,3965690,Peak concentration achieved,"Peak concentration achieved was greater in the elderly of both sexes (males: 40.2 vs. 19.5 ng/ml, P less than .005; females: 44.7 vs. 10.4 ng/ml, P less than .01).",Imipramine and desipramine disposition in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ng] / [ml],10.4,243648,DB01151,Desipramine
,3965690,half-life,Desipramine half-life was slightly prolonged in elderly males (30.8 vs. 21.2 hr; P less than .05) apparently related to a nonsignificant decrease in p.o. clearance.,Imipramine and desipramine disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,30.8,243649,DB01151,Desipramine
,3965690,half-life,Desipramine half-life was slightly prolonged in elderly males (30.8 vs. 21.2 hr; P less than .05) apparently related to a nonsignificant decrease in p.o. clearance.,Imipramine and desipramine disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,21.2,243650,DB01151,Desipramine
,9893420,weight-,"Mean pharmacokinetic parameters for the entire population included dose (3.78 +/- 1.51 mg/kg), weight- and dose-normalized serum concentration (45.41 +/- 47.39 [micrograms/L]/[mg/kg]), and DMI clearance (0.68 +/- 1.51 [L/kg]/hr).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[μg] / [l],45.41,248312,DB01151,Desipramine
,9893420,dose-normalized serum concentration,"Mean pharmacokinetic parameters for the entire population included dose (3.78 +/- 1.51 mg/kg), weight- and dose-normalized serum concentration (45.41 +/- 47.39 [micrograms/L]/[mg/kg]), and DMI clearance (0.68 +/- 1.51 [L/kg]/hr).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[μg] / [l],45.41,248313,DB01151,Desipramine
,9893420,clearance,"Mean pharmacokinetic parameters for the entire population included dose (3.78 +/- 1.51 mg/kg), weight- and dose-normalized serum concentration (45.41 +/- 47.39 [micrograms/L]/[mg/kg]), and DMI clearance (0.68 +/- 1.51 [L/kg]/hr).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[l] / [h·kg]],0.68,248314,DB01151,Desipramine
,9893420,weight-,"No between-group differences for children and adolescents were detected in dose (child, adolescent) (3.73 +/- 1.40 mg/kg, 3.83 +/- 1.68 mg/kg), weight- and dose-normalized serum concentrations (44.52 +/- 39.6 [micrograms/L]/[mg/kg], 46.34 +/- 34.89 [micrograms/L]/[mg/kg]; p = .62), and clearance (0.680 +/- 0.890 [L/kg]/hr, 0.695 +/- 1.05 [L/kg]/hr; p = .103).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[μg] / [l],44.52,248315,DB01151,Desipramine
,9893420,dose-normalized serum concentrations,"No between-group differences for children and adolescents were detected in dose (child, adolescent) (3.73 +/- 1.40 mg/kg, 3.83 +/- 1.68 mg/kg), weight- and dose-normalized serum concentrations (44.52 +/- 39.6 [micrograms/L]/[mg/kg], 46.34 +/- 34.89 [micrograms/L]/[mg/kg]; p = .62), and clearance (0.680 +/- 0.890 [L/kg]/hr, 0.695 +/- 1.05 [L/kg]/hr; p = .103).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[μg] / [l],44.52,248316,DB01151,Desipramine
,9893420,dose-normalized serum concentrations,"No between-group differences for children and adolescents were detected in dose (child, adolescent) (3.73 +/- 1.40 mg/kg, 3.83 +/- 1.68 mg/kg), weight- and dose-normalized serum concentrations (44.52 +/- 39.6 [micrograms/L]/[mg/kg], 46.34 +/- 34.89 [micrograms/L]/[mg/kg]; p = .62), and clearance (0.680 +/- 0.890 [L/kg]/hr, 0.695 +/- 1.05 [L/kg]/hr; p = .103).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[μg] / [l],46.34,248317,DB01151,Desipramine
,9893420,clearance,"No between-group differences for children and adolescents were detected in dose (child, adolescent) (3.73 +/- 1.40 mg/kg, 3.83 +/- 1.68 mg/kg), weight- and dose-normalized serum concentrations (44.52 +/- 39.6 [micrograms/L]/[mg/kg], 46.34 +/- 34.89 [micrograms/L]/[mg/kg]; p = .62), and clearance (0.680 +/- 0.890 [L/kg]/hr, 0.695 +/- 1.05 [L/kg]/hr; p = .103).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[l] / [kg],0.680,248318,DB01151,Desipramine
,9893420,clearance,"No between-group differences for children and adolescents were detected in dose (child, adolescent) (3.73 +/- 1.40 mg/kg, 3.83 +/- 1.68 mg/kg), weight- and dose-normalized serum concentrations (44.52 +/- 39.6 [micrograms/L]/[mg/kg], 46.34 +/- 34.89 [micrograms/L]/[mg/kg]; p = .62), and clearance (0.680 +/- 0.890 [L/kg]/hr, 0.695 +/- 1.05 [L/kg]/hr; p = .103).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[l] / [kg],0.695,248319,DB01151,Desipramine
,9893420,weight-,"No between-group gender differences were detected in dose (male, female) (3.83 +/- 1.55 mg, 3.39 +/- 1.84 mg), weight- and dose-normalized serum concentrations (45.15 +/- 37.76 [micrograms/L]/[mg/kg], 47.14 +/- 34.96 [micrograms/L]/mg/kg]; p = .720), and clearance (0.699 +/- 0.89 [L/kg]/hr, 0.606 +/- 0.535 [L/kg]/hr; p = .390).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[μg] / [l],45.15,248320,DB01151,Desipramine
,9893420,dose-normalized serum concentrations,"No between-group gender differences were detected in dose (male, female) (3.83 +/- 1.55 mg, 3.39 +/- 1.84 mg), weight- and dose-normalized serum concentrations (45.15 +/- 37.76 [micrograms/L]/[mg/kg], 47.14 +/- 34.96 [micrograms/L]/mg/kg]; p = .720), and clearance (0.699 +/- 0.89 [L/kg]/hr, 0.606 +/- 0.535 [L/kg]/hr; p = .390).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[μg] / [l],45.15,248321,DB01151,Desipramine
,9893420,dose-normalized serum concentrations,"No between-group gender differences were detected in dose (male, female) (3.83 +/- 1.55 mg, 3.39 +/- 1.84 mg), weight- and dose-normalized serum concentrations (45.15 +/- 37.76 [micrograms/L]/[mg/kg], 47.14 +/- 34.96 [micrograms/L]/mg/kg]; p = .720), and clearance (0.699 +/- 0.89 [L/kg]/hr, 0.606 +/- 0.535 [L/kg]/hr; p = .390).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[μg] / [l],47.14,248322,DB01151,Desipramine
,9893420,clearance,"No between-group gender differences were detected in dose (male, female) (3.83 +/- 1.55 mg, 3.39 +/- 1.84 mg), weight- and dose-normalized serum concentrations (45.15 +/- 37.76 [micrograms/L]/[mg/kg], 47.14 +/- 34.96 [micrograms/L]/mg/kg]; p = .720), and clearance (0.699 +/- 0.89 [L/kg]/hr, 0.606 +/- 0.535 [L/kg]/hr; p = .390).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[l] / [kg],0.699,248323,DB01151,Desipramine
,9893420,clearance,"No between-group gender differences were detected in dose (male, female) (3.83 +/- 1.55 mg, 3.39 +/- 1.84 mg), weight- and dose-normalized serum concentrations (45.15 +/- 37.76 [micrograms/L]/[mg/kg], 47.14 +/- 34.96 [micrograms/L]/mg/kg]; p = .720), and clearance (0.699 +/- 0.89 [L/kg]/hr, 0.606 +/- 0.535 [L/kg]/hr; p = .390).",Desipramine clearance in children and adolescents: absence of effect of development and gender. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893420/),[l] / [kg],0.606,248324,DB01151,Desipramine
,1636772,clearance,"The NE clearance was lower in CHF than in the control group (CHF 1.25 +/- 0.13, controls 2.04 +/- 0.22 l.min-1.m-2; P = 0.009).",Comparison of norepinephrine and isoproterenol clearance in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636772/),[l] / [(m)^2·min],1.25,250331,DB01151,Desipramine
,1636772,clearance,"The NE clearance was lower in CHF than in the control group (CHF 1.25 +/- 0.13, controls 2.04 +/- 0.22 l.min-1.m-2; P = 0.009).",Comparison of norepinephrine and isoproterenol clearance in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636772/),[l] / [(m)^2·min],2.04,250332,DB01151,Desipramine
,1636772,clearance,"The ISO clearance was reduced similarly in CHF (CHF 0.90 +/- 0.09, controls 1.59 +/- 0.12 l.min-1.m-2; P less than 0.001).",Comparison of norepinephrine and isoproterenol clearance in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636772/),[l] / [(m)^2·min],0.90,250333,DB01151,Desipramine
,1636772,clearance,"The ISO clearance was reduced similarly in CHF (CHF 0.90 +/- 0.09, controls 1.59 +/- 0.12 l.min-1.m-2; P less than 0.001).",Comparison of norepinephrine and isoproterenol clearance in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636772/),[l] / [(m)^2·min],1.59,250334,DB01151,Desipramine
